Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 758-767

  Cutolo, Maurizio ^a   Nadler, Steven G ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Co stimulatory molecules; CTLA 4 Ig; Endothelial cells; Macrophages; Osteoclasts; Rheumatoid arthritis

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD86 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY PRODUCTION; B LYMPHOCYTE ACTIVATION; BONE EROSION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CTLA-4 ANTIGEN; HUMANS; IMMUNOGLOBULINS; INFLAMMATION; RECOMBINANT PROTEINS;

EID: 84877819591     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.01.001     Document Type: Review

References (81)

1. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
2. Snir O., Widhe M., Hermansson M., von Spee C., Lindberg J., Hensen S., et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010, 62:44-52.
3. Mathsson L., Mullazehi M., Wick M.C., Sjoberg O., van Vollenhoven R., Klareskog L., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008, 58:36-45.
4. Kunz M., Ibrahim S.M. Non-major histocompatibility complex rheumatoid arthritis susceptibility genes. Crit Rev Immunol 2011, 31:99-114.
5. Middleton J., Americh L., Gayon R., Julien D., Aguilar L., Amalric F., et al. Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther 2004, 6:60-72.
6. Harre U., Georgess D., Bang H., Bozec A., Axmann R., Ossipova E., et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012, 122:1791-1802.
7. Atzeni F., Benucci M., Salli S., Bongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev Dec 3 2012, [pii: S1568-9972(12)00278-9]. 10.1016/j.autrev.2012.10.020.
8. Papagoras C., Voulgari P.V., Drosos A.A. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010, 9:574-582.
9. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
10. Senolt L., Vencovsky J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9:102-107.
11. Straub R., Cutolo M. EULAR compendium on rheumatic diseases 2012, BMJ, London, UK. 2nd ed.
12. Yamada A., Salama A.D., Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002, 13:559-575.
13. Haggerty H.G., Abbott M.A., Reilly T.P., DeVona D.A., Gleason C.R., Tay L., et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 2007, 34:2365-2373.
14. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
15. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
16. Schiff M., Bessette L. Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis. Clin Rheumatol 2010, 29:583-591.
17. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:437-449.
18. Janeway C.A., Travers P. Immunobiology: the immune system in health and diseases 2005, Garland Science Publishing, New York.
19. Perkins D., Wang Z., Donovan C., He H., Mark D., Guan G., et al. Regulation of CTLA-4 expression during T cell activation. J Immunol 1996, 156:4154-4159.
20. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174:561-569.
21. Linsley P.S., Nadler S.G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009, 229:307-321.
22. Davis P.M., Abraham R., Xu L., Suchard S.J. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007, 34:2204-2210.
23. Buch M.H., Boyle D.L., Rosengren S., Saleem B., Reece R.J., Rhodes L.A., et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009, 68:1220-1227.
24. Cutolo M., Soldano S., Montagna P., Sulli A., Seriolo B., Villaggio B., et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther 2009, 11:R176.
25. Weisman M.H., Durez P., Hallegua D., Aranda R., Becker J.C., Nuamah I., et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006, 33:2162-2166.
26. Yao S., Zhu Y., Zhu G., Augustine M., Zheng L., Goode D.J., et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011, 34:729-740.
27. Butte M.J., Pena-Cruz V., Kim M.J., Freeman G.J., Sharpe A.H. Interaction of human PD-L1 and B7-1. Mol Immunol 2008, 45:3567-3572.
28. Fiocco U., Sfriso P., Oliviero F., Pagnin E., Scagliori E., Campana C., et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 2008, 8:76-82.
29. Hamann D., Baars P.A., Rep M.H., Hooibrink B., Kerkhof-Garde S.R., Klein M.R., et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997, 186:1407-1418.
30. Marti L., Golmia R., Golmia A.P., Paes A.T., Guilhen D.D., Moreira-Filho C.A., et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann N Y Acad Sci 2009, 1173:334-342.
31. Scarsi M., Ziglioli T., Airo P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 2010, 37:911-916.
32. Scarsi M., Ziglioli T., Airo' P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011, 38:2105-2111.
33. Platt A.M., Gibson V.B., Patakas A., Benson R.A., Nadler S.G., Brewer J.M., et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010, 185:1558-1567.
34. Koenders M.I., Marijnissen R.J., Joosten L.A., Abdollahi-Roodsaz S., Di Padova F.E., van de Loo F.A., et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum 2012, 64:1762-1770.
35. Ndejembi M.P., Teijaro J.R., Patke D.S., Bingaman A.W., Chandok M.R., Azimzadeh A., et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006, 177:7698-7706.
36. Teijaro J.R., Njau M.N., Verhoeven D., Chandran S., Nadler S.G., Hasday J., et al. Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus. J Immunol 2009, 182:6834-6843.
37. Kasprowicz D.J., Kohm A.P., Berton M.T., Chruscinski A.J., Sharpe A., Sanders V.M. Stimulation of the B cell receptor, CD86 (B7-2), and the beta 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell. J Immunol 2000, 165:680-690.
38. Jeannin P., Delneste Y., Lecoanet-Henchoz S., Gauchat J.F., Ellis J., Bonnefoy J.Y. CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells. J Biol Chem 1997, 272:15613-15619.
39. Rau F.C., Dieter J., Luo Z., Priest S.O., Baumgarth N. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol 2009, 183:7661-7671.
40. Davidson A., Diamond B., Wofsy D., Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus 2005, 14:197-203.
41. Kin N.W., Sanders V.M. CD86 stimulation on a B cell activates the phosphatidylinositol 3-kinase/Akt and phospholipase C gamma 2/protein kinase C alpha beta signaling pathways. J Immunol 2006, 176:6727-6735.
42. Vogt B., Warncke M., Micheel B., Sheriff A. Lentiviral gene transfer of CTLA4 generates B cells with reduced costimulatory properties. Autoimmunity 2009, 42:380-382.
43. Kanbe K., Chiba J., Nakamura A. Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis. Rheumatol Int Jan 3 2012, [Epub ahead of print]. 10.1007/s00296-011-2326-8.
44. Zaiss M.M., Sarter K., Hess A., Engelke K., Bohm C., Nimmerjahn F., et al. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum 2010, 62:2328-2338.
45. Zaiss M.M., Frey B., Hess A., Zwerina J., Luther J., Nimmerjahn F., et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010, 184:7238-7246.
46. Fife B.T., Griffin M.D., Abbas A.K., Locksley R.M., Bluestone J.A.. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest 2006, 116:2252-2261.
47. Ko H.J., Cho M.L., Lee S.Y., Oh H.J., Heo Y.J., Moon Y.M., et al. CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population. J Autoimmun 2010, 34:111-120.
48. Alvarez-Quiroga C., Abud-Mendoza C., Doniz-Padilla L., Juarez-Reyes A., Monsivais-Urenda A., Baranda L., et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:588-595.
49. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003, 171:3348-3352.
50. Bluestone J.A., Liu W., Yabu J.M., Laszik Z.G., Putnam A., Belingheri M., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8:2086-2096.
51. Furuzawa-Carballeda J., Lima G., Uribe-Uribe N., Avila-Casado C., Mancilla E., Morales-Buenrostro L.E., et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant Proc 2010, 42:3489-3496.
52. Bonelli M., Ferner E., Goschl L., Bluml S., Hladik A., Karonitsch T., et al. Abatacept (CTLA-4Ig) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis (RA). Arthritis Rheum Nov 30 2012, [Epub ahead of print]. 10.1002/art.37787.
53. Colmegna I., Ohata B.R., Menard H.A. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 2012, 91:607-620.
54. Wenink M.H., Santegoets K.C., Platt A.M., van den Berg W.B., van Riel P.L., Garside P., et al. Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. Ann Rheum Dis 2012, 71:80-83.
55. Brizzolara R, Montagna P, Soldano S, Cutolo M. Evidence of short-term direct interaction between CTLA4-Ig (abatacept) and synovial macrophages from rheumatoid arthritis patients. J Rheumatol in press.
56. Davis P.M., Nadler S.G., Stetsko D.K., Suchard S.J. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 2008, 126:38-47.
57. Beinke S., Ley S.C. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004, 382:393-409.
58. Brizzolara R., Montagna P., Soldano S., Sulli A., Seriolo B., Villaggio B., et al. Evidence for NF-kB intracellular signalling involvement following CTLA4-Ig (abatacept) treatment of human macrophages. Arthritis Rheum 2012, 64:S915. [Abstract 2164].
59. Li H., Hong S., Qian J., Zheng Y., Yang J., Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 2010, 116:210-217.
60. Schett G., Harrer T., Muller-Schmucker S., Herman S., Axmann R., Zaiss M., et al. Abatacept monotherapy effectively reduces the frequency of osteoclast precursor cells in the peripheral blood of patients with rheumatoid arthritis and inhibits their differentiation into osteoclasts. Arthritis Rheum 2012, 64:S193. [Abstract 2163].
61. Kliwinski C., Kukral D., Postelnek J., Krishnan B., Killar L., Lewin A., et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 2005, 25:165-171.
62. Axmann R., Herman S., Zaiss M., Franz S., Polzer K., Zwerina J., et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008, 67:1603-1609.
63. Raemer P.C., Haemmerling S., Giese T., Canaday D.H., Katus H.A., Dengler T.J., et al. Endothelial progenitor cells possess monocyte-like antigen-presenting and T-cell-co-stimulatory capacity. Transplantation 2009, 87:340-349.
64. Abrams J.R., Kelley S.L., Hayes E., Kikuchi T., Brown M.J., Kang S., et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000, 192:681-694.
65. Kreisel D., Krupnick A.S., Balsara K.R., Riha M., Gelman A.E., Popma S.H., et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol 2002, 169:6154-6161.
66. Lozanoska-Ochser B., Klein N.J., Huang G.C., Alvarez R.A., Peakman M. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J Immunol 2008, 181:6109-6116.
67. Emery P., Durez P., Dougados M., Legerton C.W., Becker J.C., Vratsanos G., et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010, 69:510-516.
68. Patakas A., Nadler S., Brewer J., McInnes I.B., Garside P. Abatacept is highly effective in inhibiting T cell priming but fails to induce T cell tolerance after primary antigen encounter. Ann Rheum Dis 2012, 71:148.
69. Huizinga T.W.J., Emery P., Westhovens R., Le Bars M., Gaillez C., Poncet C., et al. Rate of anti-cyclic citrullinated peptide antibody and rheumatoid factor seroconversion in patients with undifferentiated arthritis or early rheumatoid arthritis treated with abatacept. Arthritis Rheum 2011, 63(Suppl. 10):2232.
70. Tay L., Leon F., Vratsanos G., Raymond R., Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007, 9:R38.
71. Conaghan P.G., Durez P., Alten R.E., Burmester G.R., Tak P.P., Klareskog L., et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis Aug 21 2012, [Epub ahead of print]. 10.1136/annrheumdis-2012-201611.
72. Zhang W., Wang B., Wang F., Zhang J., Yu J. CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats. Mol Immunol 2012, 50:150-159.
73. Saalbach A., Klein C., Sleeman J., Sack U., Kauer F., Gebhardt C. Dermal fibroblasts induce maturation of dendritic cells. J Immunol 2007, 178:4966-4974.
74. Malaviya A.P., Ostor A.J. Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology 2012, 20:59-69.
75. Furie R., Nicholls K., Cheng T.T., Houssiau F., Burgos-Vargas R., Aranda R., et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum 2011, 63:S962. [Abstract 2469].
76. Wofsy D., Meadows-Shropshire S., Hillson J.L., Diamond B. Abatacept for lupus nephritis: alternative outcome measures support opposing interpretations of data from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum 2011, 63:S964. [Abstract 2474].
77. Mease P., Genovese M.C., Gladstein G., Kivitz A.J., Ritchlin C., Tak P.P., et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011, 63:939-948.
78. Bathon J., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011, 70:1949-1956.
79. Genovese M.C., Schiff M., Luggen M., Le Bars M., Aranda R., Elegbe A., et al. Longterm safety and efficacy of abatacept through 5years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012, 39:1546-1554.
80. Kremer J.M., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Westhovens R., et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011, 70:1826-1830.
81. Westhovens R., Kremer J.M., Moreland L.W., Emery P., Russell A.S., Li T., et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009, 36:736-742.